Research programme: gene therapies - Novo Nordisk
Latest Information Update: 02 Jul 2024
At a glance
- Originator bluebird bio; Novo Nordisk
- Class Blood coagulation factors; Gene therapies
- Mechanism of Action Factor VIII modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 26 Jun 2024 Novo Nordisk acquires the Hemophilia A program and rights to MegaTAL in vivo gene editing technology from 2seventy bio
- 01 May 2023 Preclinical trials in Haemophilia A in USA, Denmark (Parenteral) before May 2023
- 07 Jan 2022 Novo Nordisk in-licenses mRNA-based megaTAL™ technology for the development of a therapy for haemophilia A from 2seventy bio